Dehydration News and Research

Latest Dehydration News and Research

Klotho hormone can protect kidney from renal fibrosis

A natural hormone known to inhibit aging can also protect kidneys against renal fibrosis, UT Southwestern Medical Center researchers have demonstrated.

15 Apr 2011

Elevated levels of sodium limit body's natural responses to stress

All those salty snacks available at the local tavern might be doing more than increasing your thirst: They could also play a role in suppressing social anxiety.

6 Apr 2011

Sickle cell trait can cause sudden death in young African-American athletes

The sickle cell trait could be a cause-albeit rare-of sudden death in young African-American competitive athletes, most commonly during football training, according to a scientific poster that will be presented at the American College of Cardiology Scientific Sessions, April 1-3, in New Orleans.

4 Apr 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).

31 Mar 2011

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix® (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC).

18 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).

4 Mar 2011

OneWorld Health receives FDA clearance for iOWH032 phase 1 trials to treat secretory diarrhea

The Institute for OneWorld Health (iOWH) announced a major milestone in the fight against cholera. The Food and Drug Administration (FDA) granted iOWH permission to begin phase 1 trials for iOWH032, a drug to treat secretory diarrhea. This is the first submission of an Investigational New Drug application for a completely new chemical entity by a non-profit of this size to receive such rapid FDA clearance, and it could be the first synthetic drug of its kind for diarrheal diseases.

2 Mar 2011

Treat discomfort not fever say the new pediatric guidelines

According to a new report from the American Academy of Pediatrics (AAP), fevers alone are not a cause for intervention in children. Dr. Janice Sullivan, the lead author of the report says, “The focus should be on comfort and not on absolute temperature.” That’s because fever can be help fight illness, by slowing down the reproduction of bacteria and viruses or stimulating the body’s immune response she explains. “That’s a benefit of fever…and may shorten the time that your child remains ill,” she adds.

28 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

Bangladesh cholera vaccine trial

Bangladesh will conduct the world’s largest clinical trial of an affordable cholera vaccine which could save tens of thousands of lives. The study began Thursday and involves nearly 250,000 people near the capital, Dhaka.

20 Feb 2011

PM Pediatrics launches new location in Bayside, Queens

PM Pediatrics, the preeminent provider of after-hours pediatric urgent care in New York, operating urgent care practices in Nassau, Suffolk and Westchester counties, today announced the launch of its newest location in Bayside, Queens. Beginning Friday, March 11, 2011, the urgent care site, located at 210-31 26th Avenue in the popular Bay Terrace Shopping Center, will open its doors to the community.

17 Feb 2011

Dengue strikes in a “vicious” way in north Qld

According to health authorities a vicious strain of Dengue fever is hospitalising people in far north Queensland. 20 people have been diagnosed with the Type 2 variant of the virus in East Innisfail and another five have Type 4 Dengue. 12 other people are possibly ill with the virus and awaiting laboratory confirmation.

15 Feb 2011

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

Napo Pharmaceuticals, Inc. is pleased to announce the positive results of a successfully completed Phase 2 study of crofelemer for the treatment of hospitalized adult patients with mild to moderate acute watery diarrhea conducted by its partner Glenmark Pharmaceuticals Ltd..

14 Feb 2011

Key advance in development of fast, simple test for detection of cholera

With cholera on the rampage in Haiti and almost 40 other countries, scientists are reporting the development of a key advance that could provide a fast, simple test to detect the toxin that causes the disease. The report appears in ACS' journal Bioconjugate Chemistry. Cholera affects more than 200,000 people annually, mainly in developing countries, and causes about 5,000 deaths. Many involve infants, children, and the elderly.

10 Feb 2011

AJN: Nurses and physicians lack knowledge about human trafficking

A report, published in the February issue of the American Journal of Nursing, underscores nurse and physicians' lack of knowledge about the indicators of human trafficking when they encounter a patient who is a victim of trafficking.

8 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

Dehydration News and Research

Latest Dehydration News and Research

Klotho hormone can protect kidney from renal fibrosis

Elevated levels of sodium limit body's natural responses to stress

Sickle cell trait can cause sudden death in young African-American athletes

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

OneWorld Health receives FDA clearance for iOWH032 phase 1 trials to treat secretory diarrhea

Treat discomfort not fever say the new pediatric guidelines

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Bangladesh cholera vaccine trial

PM Pediatrics launches new location in Bayside, Queens

Dengue strikes in a “vicious” way in north Qld

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

Key advance in development of fast, simple test for detection of cholera

AJN: Nurses and physicians lack knowledge about human trafficking

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dehydration News and Research

Latest Dehydration News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in